Running the tank to empty: How far can the car go?

Abstract

Although the importance of minimal residual disease (MRD) negativity has been well documented in acute leukemia, in this issue of Blood, Hay et al have specifically demonstrated its importance after chimeric antigen receptor (CAR) T-cell therapy, and have elucidated factors associated with durable event-free survival (EFS).